ArticleNeurochemical research2025
Effect of Dynamin-2 Gene Modified OECs on Functional and Molecular Neuroprotection After Spinal Cord Injury in Rats.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Spinal cord injury (SCI) imposes a significant economic burden on individuals and society, with limited options for repairing the central nervous system after injury. Cell transplantation therapy, particularly using olfactory ensheathing cells (OECs), has shown promise. However, the neuroprotective mechanisms underlying genetically modified OECs remain unclear. This study aimed to investigate the effects of Dynamin-2 (Dnm2) gene-modified OECs (Dnm2-OECs) on SCI repair in a rat model. OECs were harvested from three-day-old rats. Adult rats were divided into sham, SCI, SCI-OEC, and SCI-Dnm2-OECs groups. Dnm2-OECs were transplanted one day post-SCI model, and recovery was assessed through BBB scores, histological analyses, and molecular markers of inflammation. Results showed that the purity and infection efficiency of OECs were 87.28 ± 7.65% and 89.04 ± 5.56%, respectively. Dnm2-OECs survived for at least 28 days post-transplantation and significantly improved BBB scores by day 21. Additionally, neuronal counts increased, syringomyelia decreased, demyelination lessened, and mitochondrial structure improved. Dnm2 levels rose in spinal tissue, while NF-κB pathway proteins and pro-inflammatory cytokines (TRAF6, IL-17, IL-1β and TNF-α) were reduced. Microglial cells (Iba1) decreased correspondingly. These results indicate that Dnm2-OECs transplantation enhances neurological recovery after by inhibiting the NF-κB signaling pathway, offering a potential therapeutic strategy for SCI repair.
Indexed as
Identifiers
40668420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.